Biofrontera ^{Priced, Nasdaq: BFRA}

We are a German biopharmaceutical company specializing in treating dermatological conditions and diseases caused by sun damage to the skin. Our approved products focus on the treatment of actinic keratoses, which are skin lesions that can sometimes lead to skin cancer, in the U.S. and Europe, as well as the treatment of basal cell carcinoma in the EU. Actinic keratoses are cosmetically unappealing and typically appear on sun-exposed areas, such as the face, bald scalp, arms or the back of the hands, and are often elevated, flaky, and rough in texture, and appear on the skin as hyperpigmented spots. Our principal product is Ameluz, which is a prescription drug in gel form approved for use in combination with photodynamic therapy (PDT), which we sometimes refer to as Ameluz PDT. We have also developed our own PDT lamp, BF-RhodoLED. Ameluz PDT received European approval in 2011 for the treatment of mild-to-moderate actinic keratosis on the face and scalp, which has since been extended to larger areas of skin and the treatment of superficial and/or nodular basal cell carcinoma unsuitable for surgical treatment. In 2016, we received FDA approval for Ameluz PDT and launched the produced in the 4Q16. Unlike simple curettage and cryotherapy, PDT is non-invasive and can reduce visible scarring.